Literature DB >> 17540010

Amyloid precursor protein knockdown by siRNA impairs spontaneous alternation in adult mice.

Yann Senechal1, Peter H Kelly1, John F Cryan1, Francois Natt1, Kumlesh K Dev1.   

Abstract

The cleavage-product of amyloid precursor protein (APP) constitutes the core component of plaques found in the brains of Alzheimer's disease (AD) patients. APP is ubiquitously expressed and its precise physiological functions remain unclear. This protein has been proposed to regulate synaptic function and processes underlying learning and memory. While APP knockout mice show behavioral impairments, these may occur due to early changes during development and/or due to abolition of APP function in adult. To investigate the acute effects of APP knockdown without involving developmental processes, APP expression was reduced using RNA interference in adult mouse brain. Small interfering RNAs (siRNAs) that down-regulated mouse APP protein levels (APP-siRNA) were identified using an APP plasmid-siRNA co-transfection assay in mouse NIH/3T3 fibroblast cells. Infusion of APP-siRNAs into the ventricular system for 2 weeks also down-regulated APP mRNA in mouse brain. Highest knockdown of APP mRNA levels was found in the CA2-CA3 regions of the hippocampus. Mice treated with the most active APP-siRNA showed a significant reduction in spontaneous alternation rate in the Y-maze, without effects on forelimb grip strength or locomotor activity. These data suggest that acute knockdown of APP in adult mouse brain impairs hippocampus-dependent spatial working memory.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17540010     DOI: 10.1111/j.1471-4159.2007.04672.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  13 in total

Review 1.  Progress toward in vivo use of siRNAs-II.

Authors:  Garrett R Rettig; Mark A Behlke
Journal:  Mol Ther       Date:  2011-12-20       Impact factor: 11.454

Review 2.  Probing the biology of Alzheimer's disease in mice.

Authors:  Karen H Ashe; Kathleen R Zahs
Journal:  Neuron       Date:  2010-06-10       Impact factor: 17.173

3.  Dysregulation of Ca2+ signaling in astrocytes from mice lacking amyloid precursor protein.

Authors:  Cristina I Linde; Sergey G Baryshnikov; A Mazzocco-Spezzia; Vera A Golovina
Journal:  Am J Physiol Cell Physiol       Date:  2011-03-02       Impact factor: 4.249

4.  High-density lipoprotein facilitates in vivo delivery of α-tocopherol-conjugated short-interfering RNA to the brain.

Authors:  Yoshitaka Uno; Wenying Piao; Kanjiro Miyata; Kazutaka Nishina; Hidehiro Mizusawa; Takanori Yokota
Journal:  Hum Gene Ther       Date:  2011-03-21       Impact factor: 5.695

5.  Alzheimer's disease: a pathogenetic autoimmune disorder caused by herpes simplex in a gene-dependent manner.

Authors:  C J Carter
Journal:  Int J Alzheimers Dis       Date:  2010-12-29

6.  Preclinical development of siRNA therapeutics for AL amyloidosis.

Authors:  B M Hovey; J E Ward; P Soo Hoo; C J O'Hara; L H Connors; D C Seldin
Journal:  Gene Ther       Date:  2011-05-12       Impact factor: 5.250

7.  Ultrasound enhanced delivery of molecular imaging and therapeutic agents in Alzheimer's disease mouse models.

Authors:  Scott B Raymond; Lisa H Treat; Jonathan D Dewey; Nathan J McDannold; Kullervo Hynynen; Brian J Bacskai
Journal:  PLoS One       Date:  2008-05-14       Impact factor: 3.240

8.  Increased dendritic spine density and tau expression are associated with individual differences in steroidal regulation of male sexual behavior.

Authors:  Pranay Bharadwaj; Christine McInnis; Amanda M K Madden; Paul J Bonthuis; Susan Zup; Emilie F Rissman; Jin Ho Park
Journal:  PLoS One       Date:  2013-07-16       Impact factor: 3.240

Review 9.  Gene therapy in Alzheimer's disease - potential for disease modification.

Authors:  Per Nilsson; Nobuhisa Iwata; Shin-ichi Muramatsu; Lars O Tjernberg; Bengt Winblad; Takaomi C Saido
Journal:  J Cell Mol Med       Date:  2010-02-16       Impact factor: 5.310

10.  In vivo silencing of alpha-synuclein using naked siRNA.

Authors:  Jada Lewis; Heather Melrose; David Bumcrot; Andrew Hope; Cynthia Zehr; Sarah Lincoln; Adam Braithwaite; Zhen He; Sina Ogholikhan; Kelly Hinkle; Caroline Kent; Ivanka Toudjarska; Klaus Charisse; Ravi Braich; Rajendra K Pandey; Michael Heckman; Demetrius M Maraganore; Julia Crook; Matthew J Farrer
Journal:  Mol Neurodegener       Date:  2008-11-01       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.